OncoMatch/Clinical Trials/NCT06144736
PRIMETEST II - Clinical Stage II A/B Seminoma Treated With RA-RPLND
Is NCT06144736 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Adjuvant therapy with one cycle of cisplatin, etoposide and bleomycin for seminoma.
Treatment: Adjuvant therapy with one cycle of cisplatin, etoposide and bleomycin — PRIMETEST II is an interventional study involving low-volume metastatic seminoma. It explores a novel approach using robot-assisted primary retroperitoneal lymph node dissection, aiming to reduce long-term side effects and improve quality of life. By identifying factors predicting cancer recurrence, the study hopes to tailor treatments for better outcomes. The approach could potentially spare patients from chemotherapy induced long-term side effects while maintaining excellent survival rates, presenting a promising shift in testicular cancer care for this specific patient group.
Check if I qualifyExtracted eligibility criteria
Cancer type
Testicular Germ Cell Tumor
Disease stage
Required: Stage IIA, IIB
Excluded: Stage IIC, III
Metastatic disease required
Prior therapy
Must have received: carboplatin (carboplatin) — adjuvant
Recurrence of a CS I tumor after adjuvant therapy with carboplatin mono
Cannot have received: chemotherapy other than carboplatin mono
The patient received a different chemotherapy than described above
Cannot have received: retroperitoneal radiotherapy
The patient underwent retroperitoneal radiotherapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify